Apyx Medical (APYX) Receivables (2010 - 2026)

Apyx Medical has reported Receivables for 17 years, with the latest figure at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 9.53% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 9.53% YoY), and the FY2025 full-year result was $17.1 million, up 7.53% from the prior year.
• Receivables for Q1 2026 stood at $12.8 million, down from $17.1 million in the prior quarter.
• The five-year high for Receivables was $17.1 million in Q4 2025, with the low at $9.1 million in Q3 2022.
• Historically, Receivables has averaged $12.5 million across 5 years, with a median of $12.5 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables decreased 26.01% — and 2023, when it soared 45.33%.
• Apyx Medical's Receivables stood at $10.7 million in 2022, then soared by 35.7% to $14.5 million in 2023, then gained by 9.34% to $15.9 million in 2024, then advanced by 7.53% to $17.1 million in 2025, then retreated by 25.3% to $12.8 million in 2026.
• The last three Receivables figures came in at $12.8 million (Q1 2026), $17.1 million (Q4 2025), and $13.0 million (Q3 2025), per Business Quant data.